⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
JUBLPHARMA - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.2
| Stock Code | JUBLPHARMA | Market Cap | 13,580 Cr. | Current Price | 851 ₹ | High / Low | 1,250 ₹ |
| Book Value | 141 ₹ | Dividend Yield | 0.58 % | ROCE | 2.91 % | ROE | 1.04 % |
| Face Value | 1.00 ₹ | DMA 50 | 916 ₹ | DMA 200 | 1,009 ₹ | Chg in FII Hold | -0.60 % |
| Chg in DII Hold | 0.70 % | PAT Qtr | 6.60 Cr. | PAT Prev Qtr | -48.0 Cr. | RSI | 45.4 |
| MACD | -26.8 | Volume | 84,305 | Avg Vol 1Wk | 1,81,761 | Low price | 784 ₹ |
| High price | 1,250 ₹ | Debt to equity | 0.02 | 52w Index | 14.4 % | Qtr Profit Var | 154 % |
| EPS | 1.23 ₹ | Industry PE | 27.6 |
📊 Core Financials
- Revenue Growth: PAT turned positive (₹6.6 Cr vs -₹48 Cr), but remains weak
- Profit Margins: Very low with ROE at 1.04% and ROCE at 2.91%
- Debt Ratios: Debt-to-Equity at 0.02, virtually debt-free
- Cash Flows: Dividend yield of 0.58% provides modest shareholder returns
- Return Metrics: Efficiency far below industry peers
💹 Valuation Indicators
- P/E Ratio: Not meaningful due to low EPS
- P/B Ratio: ~6.0 (Price ₹851 / Book Value ₹141, trading at a premium)
- PEG Ratio: Not available, growth outlook uncertain
- Intrinsic Value: Appears stretched given weak profitability
🏢 Business Model & Competitive Advantage
- Operates in pharmaceuticals under Jubilant Group
- Competitive advantage lies in diversified pharma portfolio and group backing
- Weak profitability metrics limit sustainability despite scale
📈 Entry Zone Recommendation
- Current Price: ₹851
- Support Zone: ₹784 – ₹820 (near 52-week low, RSI at 45.4 indicates weak momentum)
- Long-term Holding: Risky due to weak returns and stretched valuation; suitable only for speculative investors betting on turnaround
✅ Positive
- Debt-free balance sheet (Debt-to-Equity 0.02)
- Dividend yield of 0.58% adds shareholder value
- DII holdings increased (+0.70%), showing domestic investor confidence
⚠️ Limitation
- ROE and ROCE very weak compared to peers
- P/B ratio high, suggesting overvaluation
- P/E not meaningful due to low EPS
📉 Company Negative News
- Quarterly PAT remains very low despite improvement
- FII holdings decreased (-0.60%), showing reduced foreign investor confidence
- Technical indicators (MACD negative, RSI weak) reflect bearish momentum
📈 Company Positive News
- Quarterly PAT improved significantly (₹6.6 Cr vs -₹48 Cr)
- DII holdings increased, reflecting domestic institutional support
🌐 Industry
- Pharmaceutical industry benefits from global healthcare demand
- Industry P/E at 27.6 highlights JUBLPHARMA trading at a steep premium despite weak earnings
🔎 Conclusion
JUBLPHARMA shows signs of recovery with PAT turning positive and a debt-free balance sheet, but profitability remains weak and valuations are stretched. Entry around ₹784–₹820 may provide a safer margin for speculative investors. Long-term holding requires caution until earnings stabilize and return ratios improve, though group backing provides strategic strength.